Stabilizing Macrophage Immune States through Fusion-Enabled Nanoparticle-Based Intracellular Drug Depots for Durable Ulcerative Colitis Therapy
ACS Nano · 2026
DOI: 10.1021/acsnano.6c03677 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Zilong Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai201203, China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Macrophages, Nanoparticles, Curcumin. Die Arbeit nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Science and Technology Innovation Talent System Construction Program of Shaanxi University of Chinese Medicine.
Abstract (Originalsprache)
Ulcerative colitis (UC) is characterized by persistent colonic inflammation accompanied by the accumulation of pro-inflammatory M1-like macrophages, which sustain cytokine production and impair mucosal repair. Promoting a shift toward a pro-resolving M2-like phenotype is therefore a promising strategy, but current macrophage-modulating approaches are often limited by insufficient intracellular drug persistence and rapid phenotypic reversion after treatment withdrawal. Herein, we report a therapeutic strategy designed to achieve prolonged immunomodulation of macrophages. Specifically, we develop an orally administrable, fusion-enabled nanoparticle (OFEN) to enable improved intracellular availability of immunomodulatory agents in macrophages. By tuning the cholesterol content of milk-derived exosome membranes, OFEN exhibited gastrointestinal stability and fusion-biased cellular entry with reduced endolysosomal sequestration. Following cellular uptake, the poly(lactic-co-glycolic acid) (PLGA) core served as an intracellular reservoir for the prolonged release of tumor necrosis factor-α (TNF-α) siRNA and curcumin, thereby combining sequence-specific suppression of a central inflammatory mediator with broader immunomodulatory and antioxidative regulation. This intracellular exposure sustained M2-associated phenotypic modulation and reduced pro-inflammatory cytokine production. In a chronic colitis model, intermittent OFEN administration alleviated disease activity, preserved colonic architecture, and promoted epithelial barrier-associated recovery, producing greater therapeutic benefit than 5-aminosalicylic acid (5-ASA) and the less fusogenic counterpart under the same intermittent dosing schedule. In a dextran sulfate sodium (DSS) rechallenge model, protective effects remained detectable at the day-12 assessment following a single oral administration of OFEN. Collectively, these findings support fusion-biased, depot-like intracellular retention as a strategy for prolonging macrophage-directed immunomodulation in UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai201203, China.
- State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai201203, China.
- School of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang712046, China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing210023, China.
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang110016, China.
- University of Chinese Academy of Sciences, Beijing100049, China.
ORCID-Profile: Yu Liu, Miaorong Yu, Yong Gan
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Science and Technology Innovation Talent System Construction Program of Shaanxi University of Chinese Medicine
- State Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers
- Shanghai "Science and Technology Innovation Action Plan" Technical Standard Project
- Natural Science Foundation of Shanghai
- SANOFI Scholarship Program
- Strategic Priority Research Program of the Chinese Academy of Sciences
Zitieren
APA
Zhang, Z., Shi, Y., Tang, Y., Zhao, J., Li, Q., Xu, A., Ding, B., Liang, L., Nie, D., Zhang, D., Jiang, X., Pan, Z., Wang, R., Liu, Y., Yu, M., & Gan, Y. (2026). Stabilizing Macrophage Immune States through Fusion-Enabled Nanoparticle-Based Intracellular Drug Depots for Durable Ulcerative Colitis Therapy. ACS Nano. https://doi.org/10.1021/acsnano.6c03677
Vancouver
Zhang Z, Shi Y, Tang Y, Zhao J, Li Q, Xu A, et al. Stabilizing Macrophage Immune States through Fusion-Enabled Nanoparticle-Based Intracellular Drug Depots for Durable Ulcerative Colitis Therapy. ACS Nano. 2026. doi:10.1021/acsnano.6c03677
BibTeX
@article{Zhang2026,
author = {Zhang, Zilong and Shi, Yanhong and Tang, Yan and Zhao, Jiazhe and Li, Qinyu and Xu, Anqi and Ding, Bingwen and Liang, Li and Nie, Di and Zhang, Dongdong and Jiang, Xiaohe and Pan, Zhenxing and Wang, Rui and Liu, Yu and Yu, Miaorong and Gan, Yong},
title = {Stabilizing Macrophage Immune States through Fusion-Enabled Nanoparticle-Based Intracellular Drug Depots for Durable Ulcerative Colitis Therapy},
journal = {ACS Nano},
year = {2026},
doi = {10.1021/acsnano.6c03677}
}
EUVIMED